Current studies into retatritide peptide reveal promising outlook for managing excess body and type 2 disease. The peptide, a dual agonist of GLP-1 and GIP receptor, seems to provide enhanced weight reduction and glucose management compared existing treatments. Further clinical trials are required to fully determine its secureness record and sustai